December 28, 2023
3 min watch
Save
VIDEO: Summit trial produces ‘exciting’ data in systemic mastocytosis
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Lindsay A.M. Rein, MD, discussed the Summit trial into treatment of systemic mastocytosis, data from which was presented at the ASH Annual Meeting and Exposition.
Rein, a hematologic oncologist at Duke Health, discussed the results of the 3-part phase 2 study, which examined treatment of nonadvanced systemic mastocytosis with bezuclastinib, an oral selective KIT D816V inhibitor, and which Rein said showed promising indications.
“I think the take home point is an exciting KIT inhibitor, with some suggestion of clinical activity and some preclinical data to support the fact that it doesn't cross the blood brain barrier, which is important,” Rein said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio interview
Disclosures:
Rein reports consulting for AbbVie, CTI Biopharma, Incyte, Merck, Novartis and Sumitomo Pharma, and receiving research funding from Blueprints Medicine, Cogent, Geron, Incyte, Karyopharm, Merck, Novartis, PharmaEssentia, Protagonist and Sumitomo Pharma.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.